PubMed Health⌕ Search

Biomedical subjects

A M Monro

Publications and source records attributed to A M Monro.

At least 37 records · Page 2Linked to original sources
PubMed1981

A carcinogenicity study in mice of a beta-adrenergic antagonist, primidolol; increased total tumour incidence without tissue specificity.

The beta-adrenergic blocking agent, primidolol hydrochloride, was administered, mixed in the diet, to mice (CD-1, Charles River, France) for 18 months. Experimental groups comprised untreated controls (100/sex) and those receiving 12.5, 25 and 50 mg drug/kg body weight (50/sex). There were no non-neoplastic lesions which could be attributed to the treatment. The pattern of tumour incidence was sex-related; in females the proportion of tumour-carrying animals was significantly higher in the top dose group (48%) than in the controls (24%), whereas in males the converse was found (30% in the top dose group vs. 48% in the controls). In the top dose female group there was no one tissue in which the tumour incidence was significantly higher than in the controls. We debate whether the analysis of total tumours in the absence of a target organ is an appropriate assay for carcinogenicity. Against a background of regulatory action towards beta-blocking agents, we discuss the possibility that the results of the present study could represent either a co-carcinogenic effect of beta-blocking agents or, alternatively, a statistical contingency.

Adrenergic beta-Antagonists↗
PubMed1975

Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses.

Serum concentrations of tinidazole and metronidazole have been measured in healthy female volunteers who received a single dose of 2 g. of each drug in a cross-over study. Bioassays against T. vaginalis showed that metronidazole achieved higher peak concentrations (mean 81 mug./ml.) than did tinidazole (mean 67 mug./ml.), while assays for unchanged drug showed higher peak concentrations of tinidazole )mean 51 mug./ml;) than of metronidazole (mean 40 mug./ml9). This discrepancy is probably due to the presence in the serum of active metabolites of metronidazole. The longer half-life of tinidazole led to significantly higher serum concentrations (by bioassay and chemical assay) of tinidazole than of metronidazole from 6 hrs onwards.

Administration, Oral↗
PubMed1975

The metabolism of tolamolol in the mouse, rat, guinea-pig, rabbit and dog.

1. [3H, 14C]Tolamolol was well absorbed after oral administration to mice, rats, guinea-pigs, rabbits and dogs. 2. The major route for excretion of radioactivity by mice, rats and guinea-pigs was the faeces; in rabbits the major route was the urine. Dogs excreted similar amounts of radioactivity by both routes. Biliary excretion of radioactivity by the rat and guinea-pig was demonstrated. 3. Tolamolol was extensively metabolized by all five species. The major metabolite in mice, rats, guinea-pigs and rabbits was the product of hydroxylation of the tolyl ring, which was excreted as such as the glucuronide and sulphate conjugates. 4. In the dog the major metabolite was the acid resulting from hydrolysis of the carbamoyl group. This acid was also excreted by the rabbit, but was only a minor metabolite in the other species studied.

Animals↗